Pandemic Influenza Plan

Objectives

The 2017 Update to the United States Department of Health and Human Services (HHS) Pandemic Influenza Plan sets a ten-year, end-to-end framework to protect health before, during and after an influenza pandemic. It aims to integrate preparedness and response across sectors and disciplines, strengthen seasonal influenza control as the foundation for pandemic readiness, and adapt action to the characteristics and severity of each event.[1][2][3]

• Strengthen surveillance, epidemiology and laboratory capacity to detect, characterise and assess seasonal, novel and zoonotic influenza viruses quickly, including antiviral resistance and vaccine effectiveness.[4][5][6]
• Implement community mitigation through evidence-based non-pharmaceutical interventions, public communication, traveller health measures and border actions proportionate to pandemic severity and stage.[6][7]
• Improve medical countermeasures, including diagnostics, vaccines, therapeutics, respiratory protective devices, antivirals and ventilators, with the objective of delivering finished pandemic vaccine doses within 12 weeks of a pandemic declaration.[8][9][10]
• Strengthen health-care preparedness so that people can access appropriate clinical and behavioural health care, services can sustain operations, and the workforce is protected during patient surges.[10][11][12]
• Enhance communications and public outreach through clear, timely, accessible and actionable information tailored to changing threats, available countermeasures and community needs.[13][14]
• Maintain scientific preparedness infrastructure and coordinate domestic and international response policy, incident management, global partnerships and capacity building.[15][16][17]

Implementation

HHS leads implementation through an integrated system linking surveillance, laboratories, research, risk assessment, countermeasure development and distribution, health-care delivery, communications, public health operations and domestic and international coordination. Delivery relies on sustained seasonal influenza activity, scalable federal support, state, local, tribal and territorial action, private-sector participation and global collaboration.[1][18][19][20]

• Apply the Pandemic Intervals Framework, Influenza Risk Assessment Tool and Pandemic Severity Assessment Framework to identify novel-virus risks, track six stages of pandemic activity, assess transmissibility and clinical severity, and adapt interventions as evidence develops.[21][22][23][24]
• Expand surveillance through whole-genome sequencing, interoperable electronic reporting, sentinel and laboratory networks, international specimen and data sharing, and innovative use of electronic health records, social media and other large-scale data sources.[5][25]
• Coordinate medical-countermeasure planning through the Public Health Emergency Medical Countermeasures Enterprise, covering research, product development, regulatory science, procurement, stockpiling, distribution, dispensing, administration and performance assessment.[8][26]
• Maintain federal antiviral and pre-pandemic vaccine stockpiles, strengthen domestic manufacturing and supply chains, modernise logistics, and expand delivery through pharmacies, retail clinics and immunisation information systems.[27][9][28]
• Use regional health-care coalitions to coordinate hospitals, public health, emergency medical services, emergency management and community partners; support remote care, telehealth, crisis standards of care, infection control and workforce resilience.[12][13]
• Develop communications plans, plain-language and multilingual materials, tested messages, trusted spokespeople, digital channels and annual exercises to ensure consistent communication across government and communities.[14][15]
• Coordinate federal action under the National Incident Management System and National Response Framework, with HHS as lead federal agency and the HHS Disaster Leadership Group supporting departmental policy coordination.[17]
• Build global preparedness with the World Health Organization, partner countries, multilateral organisations, manufacturers, researchers and civil society, including through the International Health Regulations (2005), cooperative agreements, surveillance networks, laboratory support and response exercises.[29][20][30]
• Monitor implementation through surveillance and laboratory data, vaccine-effectiveness estimates, antiviral susceptibility monitoring, risk-assessment updates, exercised plans, communication testing, countermeasure safety and effectiveness monitoring, and accountability procedures for emergency preparedness funds.[25][26][13][29]

Monitoring & Evaluation

Monitoring combines year-round domestic and global surveillance, epidemiology, laboratory diagnostics, virus characterisation, risk assessment and evaluation of public-health and medical-countermeasure interventions. Surveillance is intended to support early warning, vaccine composition, antiviral-resistance detection, pandemic planning and real-time adaptation as epidemiological and laboratory evidence emerges.[5][31]

• Strengthen global and domestic surveillance, including expanded genetic sequencing, interoperable electronic reporting, sentinel sites and laboratory capacity to detect and characterise novel influenza viruses.[18][25]
• Use automated electronic reporting from United States public-health laboratories to report approximately 80,000 influenza tests annually, and monitor seasonal vaccine effectiveness through mid-season and post-season estimates from the U.S. Flu Vaccine Effectiveness Network.[5][25]
• Expand population-based FluSurv-NET surveillance of laboratory-confirmed influenza hospitalisations to identify risk factors, assess severity and inform treatment and vaccination recommendations.[16][32]
• Apply the Pandemic Intervals Framework to track progression through investigation, recognition, initiation, acceleration, deceleration and preparation intervals, using federal and jurisdiction-specific indicators.[33][34]
• Apply the Influenza Risk Assessment Tool to assess a novel influenza A virus’s potential for sustained human transmission and significant public-health impact, repeating assessments as evidence develops.[23]
• Apply the Pandemic Severity Assessment Framework to assess transmissibility and clinical severity, initially using broad scales where data are limited and later using refined five-point transmissibility and seven-point severity scales.[24]
• Monitor vaccine protection, antiviral susceptibility, medical-countermeasure demand, distribution, dispensing, administration, clinical safety and effectiveness, including through systems for pandemic vaccine effectiveness.[19][8]
• Evaluate the effectiveness, acceptability, timing and social effects of non-pharmaceutical interventions, travel and border measures, communications strategies and health-care response arrangements.[7][13]
• Conduct clinical studies and trials to support product approval, compare vaccines and therapeutics, assess stockpiled product potency, and evaluate countermeasure safety and immunogenicity.[9][16]
• Exercise preparedness, administrative and communications arrangements, record lessons learned and use findings to improve subsequent planning and response.[15][29][30]
• Require state-level recipients of public-health emergency preparedness and response funds to establish allocation, reporting and monitoring procedures that ensure accountability to local health departments.[29]

The plan includes framework-based indicators, surveillance networks, risk assessments, fund monitoring and exercised plans, but does not specify a single consolidated indicator set, quantitative performance targets, reporting timetable, independent evaluation process or formal document-wide accountability mechanism.[21][10][17]

Costing & Financing

The plan identifies sustained resources, innovation, scientific infrastructure, education, outreach, procurement and operational readiness as necessary for influenza-pandemic preparedness, but it does not provide an overall programme budget, detailed costings, financing plan or quantified funding gap.[35][27]

• Direct resources towards surveillance and laboratories, research, genome sequencing, clinical networks, data systems, vaccine and therapeutic development, manufacturing, procurement, stockpiling, logistics and distribution.[26][16]
• Maintain federal antiviral and pre-pandemic vaccine stockpiles, domestic vaccine-manufacturing capacity and supply-chain preparedness to support timely access to medical countermeasures.[27][10]
• Update the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan annually, taking account of fiscal capabilities when directing resources to high-priority threats.[26]
• Improve funding, procurement, contracting, grants management, hiring and emergency fiscal procedures to accelerate and manage response operations accountably, including when funding is limited.[4][17]
• Prioritise and leverage limited resources for high-risk regions and resource-limited countries through domestic and international partnerships and capacity-building arrangements.[20][30]

Historical and prospective economic evidence underlines the potential cost of inadequate preparedness: twentieth-century influenza pandemics caused hundreds of billions of dollars in losses, and a moderate unmitigated pandemic comparable with those in 1957 and 1968 was estimated to have direct and indirect health costs approaching 181 billion US dollars, excluding trade disruption and other business and industry costs.[1][31]

The 2014-2015 highly pathogenic avian influenza outbreak in the United States cost federal taxpayers more than 950 million US dollars.[3]The supplied material does not specify budget allocations, financing sources, expenditure totals, resource-mobilisation targets, economic assumptions for implementation or quantified funding gaps.[18][14]